Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis

Genes Chromosomes and Cancer

Volumn 49, Issue 4, 2010, Pages 353-367

  Sato, Nagato ^a,b   Koinuma, Junkichi ^a   Ito, Tomoo ^c   Tsuchiya, Eiju ^d   Kondo, Satoshi ^b   Nakamura, Yusuke ^a   Daigo, Yataro ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN TBC1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; NONHUMAN; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTPASE-ACTIVATING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS; ORGAN SPECIFICITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 77949415631     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20747     Document Type: Article

References (50)

1. Bernards A. 2003. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 1603:47-82.
2. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PD, Caldas C. 2003. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12:27-34.
3. Callagy G, Pharoah P, Chin SF, Sangan T, Daigo Y, Jackson L, Caldas C. 2005. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 205:388-396.
4. Chavrier P, Goud B. 1999. The role of ARF and Rab GTPases in membrane transport. Curr Opin Cell Biol 11:466-475.
5. Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T, Gonzalez M, Sangan T, Earl H, Caldas C. 2003. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 56:275-279.
6. Consortium TEC, 1T. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315.
7. Daigo Y, Nakamura Y. 2008. From cancer genomics to thoracic oncology: Discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg 56:43-53.
8. Dunleavy EM, Roche D, Tagami H, Lacoste N, Ray-Gallet D, Nakamura Y, Daigo Y, Nakatani Y, Almouzni-Pettinotti G. 2009. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 137:485-497.
9. Furukawa C, Daigo Y, Ishikawa N, Kato T, Ito T, Tsuchiya E, Sone S, Nakamura Y. 2005. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 65:7102-7110.
10. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y. 2006. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 66:10339-10348.
11. Hayama S, Daigo Y, Yamabuki T, Hirata D, Kato T, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y. 2007. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 67:4113-4122.
12. Hirata D, Yamabuki T, Miki D, Ito T, Tsuchiya E, Fujita M, Hosokawa M, Chayama K, Nakamura Y, Daigo Y. 2009. Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 15:256-266.
13. Huang J, Dibble CC, Matsuzaki M, Manning BD. 2008. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28:4104-4115.
14. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. 2004. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 10:8363-8370.
15. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. 2005. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65:9176-9184.
16. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. 2006. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 97:737-745.
17. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. 2007. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 67:11601-11611.
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
19. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. 2003. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 1:485-499.
20. Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, Sone S, Nakamura Y. 2004. Prediction of sensitivity of advanced nonsmall cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 13:3029-3043.
21. Kato T, Daigo Y, Hayama S, Ishikawa N, Yamabuki T, Ito T, Miyamoto M, Kondo S, Nakamura Y. 2005. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 65:5638-5646.
22. Kato T, Hayama S, Yamabuki T, Ishikawa N, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. 2007a. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 13:434-442.
23. Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M, Kondo S, Nakamura Y, Daigo Y. 2007b. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 67:8544-8553.
24. Kato T, Sato N, Takano A, Miyamoto M, Nishimura H, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. 2008. Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res 14:2363-2370.
25. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. 2003. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22:2192-2205.
26. Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, Nakamura Y. 2006. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 28:799-805.
27. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. 2009. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 100:1502-1509.
28. Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, Bissell MJ. 2006. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci USA 103:4134-4139.
29. Machin D, Cambel M, Fayers P, Pinol A. 1997. Sample Size Tables for Clinical Studies, 2nd ed. Oxford, UK: Blackwell Science, pp. 174-253.
30. Mano Y, Takahashi K, Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Tsuchiya E, Nakamura Y, Daigo Y. 2007. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 98:1902-1913.
31. Masuda-Robens JM, Kutney SN, Qi H, Chou MM. 2003. The TRE17 oncogene encodes a component of a novel effector pathway for Rho GTPases Cdc42 and Rac1 and stimulates actin remodeling. Mol Cell Biol 23:2151-2161.
32. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. 2008. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 99:1448-1454.
33. Neuwald AF. 1997. A shared domain between a spindle assembly checkpoint protein and Ypt/Rab-specific GTPase-activators. Trends Biochem Sci 22:243-244.
34. Pei L, Peng Y, Yang Y, Ling XB, Van Eyndhoven WG, Nguyen KC, Rubin M, Hoey T, Powers S, Li J. 2002. PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res 62:5420-5424.
35. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. 2009. Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531.
36. Sato N, Koinuma J, Fujita M, Hosokawa M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. Activation of WD repeat and HMG-box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res (in press).
37. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98.
38. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132.
39. Sobin L, Wittekind C. 2002. TNM Classification of Malignant Tumors, 6th ed. New York: Wiley-Liss.
40. Sozzi G. 2001. Molecular biology of lung cancer. Eur J Cancer 37 (Suppl 7):S63-S73.
41. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. 2007. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 98:1803-1808.
42. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. 2003. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 63:7038-7041.
43. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E, Nakamura Y. 2005. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 65:11314-11325.
44. Suzuki C, Takahashi K, Hayama S, Ishikawa N, Kato T, Ito T, Tsuchiya E, Nakamura Y, Daigo Y. 2007. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 6:542-551.
45. Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, Ito T, Nishimura H, Tsuchiya E, Nakamura Y, Daigo Y. 2006. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 66:9408-9419.
46. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. 2009. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 69:6694-6703.
47. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, Nakamura Y. 2006. Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol 29:567-575.
48. Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. 2007. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 13:6624-6631.
49. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Kondo S, Nakamura Y, Daigo Y. 2007. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67:2517-2525.
50. Zerial M, McBride H. 2001. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2:107-117.